Key Points
- SVP Daniel Long sold 3,501 shares of Septerna on Nov. 10 at an average price of $18.06 (totaling $63,228), trimming his holding by 3.63% to 92,911 shares; the trade was disclosed in an SEC filing.
- Septerna rallied 16.8% to $22.47 on heavy volume despite reporting a Q3 miss—EPS of -$0.09 versus a $0.19 estimate and revenue of $21.5M versus $24.5M—alongside negative margins and a negative return on equity.
- Analysts are mostly bullish (five Buys, one Sell) with a consensus rating of Moderate Buy and a consensus price target of $30.25, while several institutional investors have recently increased their stakes.
Septerna, Inc. (NASDAQ:SEPN - Get Free Report) SVP Daniel Long sold 3,501 shares of Septerna stock in a transaction on Monday, November 10th. The shares were sold at an average price of $18.06, for a total value of $63,228.06. Following the sale, the senior vice president directly owned 92,911 shares of the company's stock, valued at approximately $1,677,972.66. The trade was a 3.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Septerna Trading Up 16.8%
SEPN traded up $3.23 during trading on Friday, hitting $22.47. The stock had a trading volume of 859,448 shares, compared to its average volume of 573,670. Septerna, Inc. has a 12 month low of $4.17 and a 12 month high of $28.99. The firm has a market cap of $1.01 billion and a PE ratio of -14.89. The company has a 50 day simple moving average of $19.17 and a 200-day simple moving average of $13.65.
Septerna (NASDAQ:SEPN - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.19 by ($0.28). Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%.The firm had revenue of $21.50 million during the quarter, compared to the consensus estimate of $24.50 million. As a group, sell-side analysts anticipate that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on SEPN shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of Septerna in a research report on Friday, September 5th. Wells Fargo & Company upgraded Septerna from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $18.00 to $28.00 in a research note on Friday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Septerna in a research note on Wednesday, October 8th. HC Wainwright increased their price objective on Septerna from $26.00 to $30.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, Wall Street Zen downgraded shares of Septerna from a "hold" rating to a "sell" rating in a research report on Saturday, November 8th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.25.
Get Our Latest Stock Analysis on Septerna
Institutional Investors Weigh In On Septerna
Large investors have recently bought and sold shares of the company. Covestor Ltd increased its position in Septerna by 55.8% during the third quarter. Covestor Ltd now owns 3,620 shares of the company's stock worth $68,000 after purchasing an additional 1,296 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company's stock valued at $107,000 after purchasing an additional 1,315 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Septerna in the third quarter valued at about $36,000. BNP Paribas Financial Markets increased its stake in shares of Septerna by 88.0% during the third quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company's stock worth $78,000 after acquiring an additional 1,945 shares during the period. Finally, Rhumbline Advisers grew its stake in shares of Septerna by 16.6% during the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company's stock worth $135,000 after purchasing an additional 3,323 shares during the period.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
